UnitedHealthcare of New Mexico, Inc. dba UnitedHealthcare Community Plan (NM) (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/7/2018 3				
The	Auditor lock has been	applied to this subm	ission.	
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and Screening				
Adult BMI Assessment (aba)		81.75%	R	Reportable
Weight Assessment and Counseling for Nutrition and				
Physical Activity for Children/Adolescents				
(wcc)				
BMI Percentile		54.26%	R	Reportable
Counseling for Nutrition		52.07%	R	Reportable
Counseling for Physical Activity		44.04%	R	Reportable
Childhood Immunization Status (cis)				
DTaP		71.78%	R	Reportable
IPV		84.43%	R	Reportable
MMR		83.45%	R	Reportable
HiB		85.40%	R	Reportable
Hepatitis B		83.70%	R	Reportable
VZV		82.48%	R	Reportable
Pneumococcal Conjugate		72.26%	R	Reportable
Hepatitis A		81.51%	R	Reportable
Rotavirus		73.24%	R	Reportable
Influenza		51.58%	R	Reportable
Combination #2		69.34%	R	Reportable
Combination #3		65.21%	R	Reportable
Combination #3		64.72%	R	Reportable
Combination #5		58.64%	R	Reportable
Combination #6		43.31%	R	Reportable
Combination #6 Combination #7			R	
		58.15%		Reportable
Combination #8		43.31%	R	Reportable
Combination #9		39.90%	R	Reportable
Combination #10		39.90%	R	Reportable
Immunizations for Adolescents (ima)				
Meningococcal		56.45%	R	Reportable
Tdap		76.16%	R	Reportable
HPV		23.84%	R	Reportable
Combination #1		54.50%	R	Reportable
Combination #2		19.95%	R	Reportable
Lead Screening in Children (Isc)		35.04%	R	Reportable
Breast Cancer Screening (bcs)		53.91%	R	Reportable
Cervical Cancer Screening (ccs)		40.35%	R	Reportable
Chlamydia Screening in Women (chl)				
16-20 Years		37.90%	R	Reportable
21-24 Years		53.52%	R	Reportable
Total		47.90%	R	Reportable
Effectiveness of Care: Respiratory Conditions				
Appropriate Testing for Children with Pharyngitis (cwp)	Υ	67.99%	R	Reportable
11. 1	'	07.9978	, ,	Reportable
Use of Spirometry Testing in the Assessment and				
Diagnosis		23.60%	R	Reportable
of COPD (spr)				
Pharmacotherapy Management of COPD Exacerbation	Υ			
(pce)		07.070/		Danastable
Systemic Corticosteroid		67.27%	R	Reportable
Bronchodilator		81.98%	R	Reportable
78080	Y	10.0101		
5-11 Years: Medication Compliance 50%		46.81%	R	Reportable
5-11 Years: Medication Compliance 75%		21.28%	R	Reportable
12-18 Years: Medication Compliance 50%		48.72%	R	Reportable
12-18 Years: Medication Compliance 75%		25.64%	R	Reportable
19-50 Years: Medication Compliance 50%		64.68%	R	Reportable
19-50 Years: Medication Compliance 75%		42.66%	R	Reportable
51-64 Years: Medication Compliance 50%		75.00%	R	Reportable
51-64 Years: Medication Compliance 75%		50.68%	R	Reportable
Total: Medication Compliance 50%		64.82%	R	Reportable
Total: Medication Compliance 75%		41.59%	R	Reportable

UnitedHealthcare of New Mexico, Inc. dba UnitedHealthcare Community Plan (NM) (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/7/2018 3:10:54 PM The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
5-11 Years	Belletit Offered	75.00%	R R	Reportable
12-18 Years		53.70%	R	Reportable
19-50 Years		49.84%	R	Reportable
51-64 Years		56.73%	R	Reportable
Total		54.53%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions		54.55 /6	K	Reportable
Controlling High Blood Pressure (cbp)		54.99%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart				•
Attack (pbh)	Y	69.09%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		72.38%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		66.67%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		70.25%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		70.00%	R	Reportable
Received Statin Therapy: Total		71.40%	R	Reportable
Statin Adherence 80%: Total		68.17%	R	Reportable
Effectiveness of Care: Diabetes				-1
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		89.29%	R	Reportable
HbA1c Poor Control (>9.0%)		45.50%	R	Reportable
HbA1c Control (<8.0%)		45.26%	R	Reportable
HbA1c Control (<8.0%) HbA1c Control (<7.0%)		45.20%	NQ NQ	Not Required
		FC 200/		
Eye Exam (Retinal) Performed		56.20%	R	Reportable
Medical Attention for Nephropathy		89.78%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		66.18%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		55.76%	R	Reportable
Statin Adherence 80%		59.11%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions				
Disease-Modifying Anti-Rheumatic Drug Therapy in	Υ	70.96%	R	Reportable
Rheumatoid Arthritis (art)	· L	7 0.0070	1.	repertable
Effectiveness of Care: Behavioral Health				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		52.32%	R	Reportable
Effective Continuation Phase Treatment		37.48%	R	Reportable
Follow-Up Care for Children Prescribed ADHD	Υ			
Medication (add)	·			
Initiation Phase		38.89%	R	Reportable
Continuation and Maintenance (C&M) Phase		33.33%	NA	Small Denominator
Follow-Up After Hospitalization for Mental Illness (fuh)	Υ			
30-Day Follow-Up		58.99%	R	Reportable
7-Day Follow-Up		35.25%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
30-Day Follow-Up		48.13%	R	Reportable
7-Day Follow-Up		32.44%	R	Reportable
Follow-Up After Emergency Department Visit for	· ·			,
Alcohol and Other Drug Abuse or Dependence (fua)	Y			
30-Day Follow-Up: 13-17 Years		0.00%	NA	Small Denominator
7-Day Follow-Up: 13-17 Years		0.00%	NA	Small Denominator
30-Day Follow-Up: 18+ Years		14.80%	R	Reportable
7-Day Follow-Up: 18+ Years		7.85%	R	Reportable
30-Day Follow-Up: Total		14.69%	R	Reportable
7-Day Follow-Up: Total		7.80%	R	Reportable
Diabetes Screening for People With Schizophrenia or		1.5070	- '`	Roportable
Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	76.40%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		62.23%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular		75.00%	NA	Small Denominator

UnitedHealthcare of New Mexico, Inc. dba UnitedHealthca None, Contract Number: None)	are Community Plan ((NM) (Org ID: 1282	29, SubID: 10138, Medica	id, Spec Area: None, Spec Proj:
Measurement Year - 2017; Date & Timestamp - 6/7/2018 3				
	Auditor lock has been a	• • • • • • • • • • • • • • • • • • • •		
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	57.37%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		26.00%	R	Reportable
12-17 Years		33.78%	R	Reportable
Total		30.40%	R	Reportable
Effectiveness of Care: Medication Management				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
ACE Inhibitors or ARBs		84.60%	R	Reportable
Diuretics		87.16%	R	Reportable
Total		85.52%	R	Reportable
Effectiveness of Care: Overuse/Appropriateness				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.10%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	91.13%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	29.90%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		71.91%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children		71.9170	K	Теропале
and Adolescents (apc)	Y			
1-5 Years			NA	Small Denominator
6-11 Years		2.22%	R	Reportable
12-17 Years		7.27%	R	Reportable
Total		5.00%	R	Reportable
Use of Opioids at High Dosage (uod)	Y		NQ	Not Required
Use of Opioids From Multiple Providers (uop)	Υ			·
Multiple Prescribers			NQ	Not Required
Multiple Pharmacies			NQ	Not Required
Multiple Prescribers and Multiple Pharmacies			NQ	Not Required
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		68.97%	R	Reportable
45-64 Years		81.89%	R	Reportable
65+ Years		96.86%	R	Reportable
Total		76.16%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		95.78%	R	Reportable
25 Months - 6 Years		82.97%	R	Reportable
7-11 Years		82.65%	R	Reportable
12-19 Years	V	82.83%	R	Reportable
Annual Dental Visit (adv) 2-3 Years	Y	54.23%	В	Panartable
2-3 Years 4-6 Years		66.78%	R R	Reportable Reportable
7-10 Years		69.75%	R	Reportable Reportable
7-10 Tears 11-14 Years		65.82%	R	Reportable
15-18 Years		56.03%	R	Reportable
19-20 Years		38.81%	R	Reportable
Total		61.02%	R	Reportable
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		28.57%	NA	Small Denominator
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		0.00%	NA	Small Denominator
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years			NA	Small Denominator

UnitedHealthcare of New Mexico, Inc. dba UnitedHealthcare Community Plan (NM) (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/7/2018 3	:10:54 PM			
The	Auditor lock has been	applied to this subm	ission.	
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Opioid abuse or dependence: Engagement of AOD			NA	Small Denominator
Treatment: 13-17 Years Other drug abuse or dependence: Initiation of AOD				
Treatment: 13-17 Years		56.90%	R	Reportable
Other drug abuse or dependence: Engagement of AOD		45 500/	В	December
Treatment: 13-17 Years		15.52%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		52.31%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		13.85%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment:		39.31%	R	Reportable
18+ Years Alcohol abuse or dependence: Engagement of AOD				
Treatment: 18+ Years		11.45%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment:		40, 400/		Denestable
18+ Years		43.40%	R	Reportable
Opioid abuse or dependence: Engagement of AOD		22.32%	R	Reportable
Treatment: 18+ Years Other drug abuse or dependence: Initiation of AOD				
Treatment: 18+ Years		40.88%	R	Reportable
Other drug abuse or dependence: Engagement of AOD		44.000/	Б	Dependable
Treatment: 18+ Years		11.23%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		39.20%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		13.86%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment:		39.24%	R	Reportable
Total Alcohol abuse or dependence: Engagement of AOD				·
Treatment: Total		11.37%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment:		42.400/	R	Dependents
Total		43.40%	K	Reportable
Opioid abuse or dependence: Engagement of AOD		22.32%	R	Reportable
Treatment: Total Other drug abuse or dependence: Initiation of AOD				· · · · · · · · · · · · · · · · · · ·
Treatment: Total		41.38%	R	Reportable
Other drug abuse or dependence: Engagement of AOD		44.000/	Б	Dependable
Treatment: Total		11.36%	R	Reportable
Total: Initiation of AOD Treatment: Total		39.39%	R	Reportable
Total: Engagement of AOD Treatment: Total		13.86%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		68.86%	R	Reportable
Postpartum Care		56.20%	R	Reportable
Use of First-Line Psychosocial Care for Children and	Υ			
Adolescents on Antipsychotics (app) 1-5 Years		25.00%	NA	Small Denominator
6-11 Years		75.00%	NA NA	Small Denominator
12-17 Years		73.33%	R	Reportable
Total		69.57%	R	Reportable
Utilization		09.57 /0	IX .	reportable
Well-Child Visits in the First 15 Months of Life (w15)				
O Visits		1.46%	R	Reportable
1 Visit		2.92%	R	Reportable
2 Visits		3.16%	R	Reportable
3 Visits		3.41%	R	Reportable
4 Visits		6.33%	R	Reportable
5 Visits		11.44%	R	Reportable
6+ Visits		71.29%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth		57.18%	i	•
Years of Life (w34)			R	Reportable
Adolescent Well-Care Visits (awc)		43.55%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NR	Not Reported
Ambulatory Care: Disabled (ambc)			NR	Not Reported
Ambulatory Care: Other (ambd)			NR	Not Reported
Inpatient UtilizationGeneral Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Dual				
Eligibles (ipub)			NR	Not Reported
9/				

UnitedHealthcare of New Mexico, Inc. dba UnitedHealthcare Community Plan (NM) (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/7/2018 3	:10:54 PM			
	Auditor lock has been		nission.	
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Υ		NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Υ		NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NR	Not Reported
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NR	Not Reported
Mental Health Utilization: Disabled (mptc)	Y		NR	Not Reported
Mental Health Utilization: Other (mptd)	Y		NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Υ		NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	Y		NR	Not Reported
Antibiotic Utilization: Other (abxd)	Y		NR	Not Reported
Standardized Healthcare-Associated Infection Ratio (hai)			NQ	Not Required
Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive Information				
Board Certification (bcr)			R	Reportable
Enrollment by Product Line: Total (enpa)			NQ	Not Required
Enrollment by Product Line: Dual Eligibles (enpb)			NQ	Not Required
Enrollment by Product Line: Disabled (enpc)			NQ	Not Required
Enrollment by Product Line: Other (enpd)			NQ	Not Required
Enrollment by State (ebs)			NQ	Not Required
Language Diversity of Membership (Idm)			NQ	Not Required
Race/Ethnicity Diversity of Membership (rdm)			NQ	Not Required
Total Membership (tlm)			NQ	Not Required
Measures Collected using Electronic Clinical Data System	ms			
Depression Screening and Follow-Up for Adolescents				
and Adults (dsf)				
Depression Screening: Total Total			ND	
			NR NB	Not Reported
Follow-up on Positive Screen: Total Total			NR NR	Not Reported Not Reported
Utilization of the PHQ-9 to Monitor Depression				
Utilization of the PHQ-9 to Monitor Depression Symptoms				
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total			NR	•
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total Depression and Remission or Response for			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total Depression and Remission or Response for Adolescents and Adults (drr)			NR NR	Not Reported Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total Depression and Remission or Response for Adolescents and Adults (drr) Follow-up PHQ-9: Total Total			NR NR NR	Not Reported Not Reported Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total Depression and Remission or Response for Adolescents and Adults (drr) Follow-up PHQ-9: Total Total Depression Remission: Total Total			NR NR NR NR NR	Not Reported Not Reported Not Reported Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms) Utilization of PHQ-9: Total Total Depression and Remission or Response for Adolescents and Adults (drr) Follow-up PHQ-9: Total Total Depression Remission: Total Total Depression Response: Total Total			NR NR NR NR NR	Not Reported Not Reported Not Reported Not Reported